REG - Cambridge Cognition - Notice of Results

Cambridge Cognition HoldingsAnnouncement

20/08/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240820:nRST0016Ba&default-theme=true

RNS Number : 0016B  Cambridge Cognition Holdings PLC  20 August 2024

 

20 August 2024

 

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

 

Notice of Results

 

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets
digital solutions to assess brain health, will announce its unaudited interim
results for the six months ended 30 June 2024 on Thursday 22 August 2024.

 

 

Enquiries:

 

 Cambridge Cognition Holdings plc                    Tel: 012 2381 0700

 Matthew Stork, Chief Executive Officer
 Panmure Liberum Limited (NOMAD and Joint Broker)

 Will Goode / Freddy Crossley / Mark Rogers          Tel: 020 7886 2968

 Rupert Dearden                                      (Corporate Finance)

                                                     (Corporate Broking)
 Dowgate Capital Limited (Joint Broker)

 David Poutney / James Serjeant                      Tel: 020 3903 7715

 Hudson Sandler (Financial PR and IR)

 Dan de Belder / Hattie Dreyfus                      Tel: 020 7796 4133

                           cog@hudsonsandler.com (mailto:cog@hudsonsandler.com)

 

Notes to Editors

 

About Cambridge Cognition

 

Cambridge Cognition is a technology company developing digital health products
to better understand, detect and treat conditions affecting brain health. The
Company's software products assess cognitive health in patients worldwide to
improve clinical trial outcomes, identify and stratify patients early and
improve global efficiency in pharmaceutical and healthcare industries.

 

For further information visit: https://cambridgecognition.com/
(https://cambridgecognition.com/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORBCGDILBBDGSC